TrialCell reports. Medicine2023

Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study.

Wataru Akahata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.